Literature DB >> 20711160

Antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on Candida albicans.

Silvia-Edith Calamari1, María-Alejandra Bojanich, Silvina-Ruth Barembaum, Nora Berdicevski, Ana-Isabel Azcurra.   

Abstract

OBJECTIVE: The aim of this work was to assess the antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on virulence factors of Candida albicans. STUDY
DESIGN: Ten isolated strains of Candida albicans obtained from 10 patients with oral candidiasis and a collection strain of C. albicans were treated with antifungal agents in different concentrations or combinations of them. Virulence factors analyzed were the cell surface hydrophobicity, the germinative tube development, the phospholipase activity and the post-antifungal effect of that exposure.
RESULTS: Virulence factors of the isolated strains obtained from patients together with the collection strain showed significant decreases with the different antifungal treatments, except for hydrophobicity and phospholipase activity. The development of germinative tube was the most sensitive factor to all the antifungal agents used. Untreated strains as well as the ones treated with antifungal agents showed a positive correlation among the virulence factors analyzed. No synergic effects arose from the combinations of the used drugs.
CONCLUSIONS: C. albicans isolated strains from patients showed high phospholipase activity and germinative tube production, which corroborates their capacity to infect the oral mucosa and the high prevalence of species. As a whole, our results imply that short exposures to sub-inhibitory concentrations of the antifungal agents under analysis, isolated or combined, can modulate the way virulence factors get manifested, thus decreasing their pathogenicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20711160     DOI: 10.4317/medoral.16.e23

Source DB:  PubMed          Journal:  Med Oral Patol Oral Cir Bucal        ISSN: 1698-4447


  7 in total

1.  Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study.

Authors:  Hanane Yousfi; Carole Cassagne; Stéphane Ranque; Jean-Marc Rolain; Fadi Bittar
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 2.  Engineering Polymeric Nanosystems against Oral Diseases.

Authors:  Valeria Mercadante; Edoardo Scarpa; Valeria De Matteis; Loris Rizzello; Alessandro Poma
Journal:  Molecules       Date:  2021-04-13       Impact factor: 4.411

3.  Chelating and antibacterial properties of chitosan nanoparticles on dentin.

Authors:  Aldo Del Carpio-Perochena; Clovis Monteiro Bramante; Marco Antonio Hungaro Duarte; Marcia Regina de Moura; Fauze Ahmad Aouada; Anil Kishen
Journal:  Restor Dent Endod       Date:  2015-03-30

4.  Synthesis, characterization, and evaluation of the antifungal properties of tissue conditioner incorporated with essential oils-loaded chitosan nanoparticles.

Authors:  Hina Ashraf; Hashmat Gul; Bushra Jamil; Asfia Saeed; Mehwish Pasha; Muhammad Kaleem; Abdul Samad Khan
Journal:  PLoS One       Date:  2022-08-19       Impact factor: 3.752

5.  Effects of Aloe Vera and Chitosan Nanoparticle Thin-Film Membranes on Wound Healing in Full Thickness Infected Wounds with Methicillin Resistant Staphylococcus Aureus.

Authors:  Reza Ranjbar; Alireza Yousefi
Journal:  Bull Emerg Trauma       Date:  2018-01

6.  Role of chitosan on controlling the characteristics and antifungal activity of bioadhesive fluconazole vaginal tablets.

Authors:  Rawan A Fitaihi; Fadilah S Aleanizy; Samar Elsamaligy; Hanaa A Mahmoud; Mohsen A Bayomi
Journal:  Saudi Pharm J       Date:  2017-12-23       Impact factor: 4.330

7.  Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts.

Authors:  Monica Ganan; Silje B Lorentzen; Berit B Aam; Vincent G H Eijsink; Peter Gaustad; Morten Sørlie
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.